12,289 Shares in STAAR Surgical (NASDAQ:STAA) Bought by Counterpoint Mutual Funds LLC

Counterpoint Mutual Funds LLC bought a new position in STAAR Surgical (NASDAQ:STAA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 12,289 shares of the medical instruments supplier’s stock, valued at approximately $298,000.

Other institutional investors have also recently bought and sold shares of the company. Quarry LP bought a new position in STAAR Surgical in the 3rd quarter worth $50,000. Quest Partners LLC bought a new position in STAAR Surgical in the 3rd quarter worth $128,000. Larson Financial Group LLC raised its holdings in STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after acquiring an additional 2,135 shares during the period. FMR LLC increased its holdings in shares of STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock worth $263,000 after purchasing an additional 3,136 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of STAAR Surgical during the 4th quarter worth about $292,000. Institutional investors own 96.70% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on STAA. Stephens restated an “equal weight” rating and set a $17.00 price objective on shares of STAAR Surgical in a report on Tuesday. StockNews.com downgraded shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Piper Sandler dropped their price objective on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 12th. William Blair downgraded shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Finally, Canaccord Genuity Group dropped their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.29.

Insider Buying and Selling at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock in a transaction on Monday, March 3rd. The shares were purchased at an average cost of $16.64 per share, for a total transaction of $4,151,729.92. Following the completion of the transaction, the insider now directly owns 11,953,198 shares in the company, valued at approximately $198,901,214.72. This represents a 2.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought a total of 834,343 shares of company stock worth $13,653,542 over the last ninety days. Corporate insiders own 1.00% of the company’s stock.

STAAR Surgical Stock Up 3.8 %

NASDAQ STAA opened at $18.28 on Wednesday. The stock has a market cap of $901.66 million, a P/E ratio of -44.59 and a beta of 0.66. The company’s 50-day simple moving average is $20.18 and its 200 day simple moving average is $25.92. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.